Calcium Dobesilate

ApprovedSmall molecule

GGuizhou Bailing Group Pharmaceutical Co Ltd

Calcium Dobesilate is one of 143 small molecule programs targeting Varicose veins. It is currently in Approved.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

Varicose VeinsActive, not recruiting

RosaceaActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

COVID-19Active, not recruiting

Diabetic RetinopathyActive, not recruiting

Ovarian Hyperstimulation SyndromeActive, not recruiting

Non-Proliferative Diabetic RetinopathyActive, not recruiting

Varicose VeinsApproved

Active, not recruiting

RosaceaPhase 1

Active, not recruiting

Type 2 Diabetes MellitusPhase 2/Phase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Diabetic RetinopathyApproved

Active, not recruiting

Ovarian Hyperstimulation SyndromePhase 2/Phase 3

Active, not recruiting

Non-Proliferative Diabetic RetinopathyApproved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Calcium Dobesilate

GGuizhou Bailing Group Pharmaceutical Co Ltd

Approved

1 2

Tricor

JJagotec

Preclinical

1 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 4

Statin

Bristol-Myers Squibb

Preclinical

1 5

Blood Taken

HHospices Civils de Lyon

Preclinical

1 6

Coronavac COVID-19 Vaccine

HHospital Moinhos de Vento

Preclinical

2 7

SARS-Cov-2 Bivalent MRNA Vaccine

AAIM Vaccine Co., Ltd.

Preclinical

2 8

AZD 1222

UUniversity Medicine Greifswald

Preclinical

2 9

Huashi Baidu Granule

XXiyuan Hospital of China Academy of Chinese Medical Sciences

Preclinical

1 10

Administration of Almitrine

CCentre Hospitalier Universitaire de Nice

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Varicose Veins

NCT07390097

Clinical

Trials by Indication[1]

Ovarian Hyperstimulation Syndrome2 trials

Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

Completed·—·Phase 2/3·NCT02271360·200 enrolled

Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome

Completed·Kkhalid abd aziz mohamed·Phase 2/3·NCT02290002·200 enrolled

Non-Proliferative Diabetic Retinopathy2 trials

Using Calcium Dobesilate to Treat Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy

Unknown status·ZZhongda Hospital·Phase 4·NCT04283162·1,200 enrolled

Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy

Unknown status·GGuizhou Bailing Group Pharmaceutical Co Ltd·Phase 2·NCT05007262·240 enrolled

COVID-191 trial

Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.

Completed·HHervé SPECHBACH·Phase 2·NCT05305508·74 enrolled

Blood Loss1 trial

Treatment of Copper Intra Uterine Device Associated Heavy Menstrual Blood Loss

Unknown status·—·Phase 3·NCT03139422·140 enrolled

Varicose veins1 trial

Calcium Dobesilate After Radiofrequency Ablation for Varicose Veins

Not yet recruiting·OOguz Arslanturk·Phase 4·NCT07390097·250 enrolled

9 more indications

Efficacy and Safety1 trial

A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon®

Completed·HHanyang University·Phase 4·NCT03962296·153 enrolled

Tics1 trial

Bioavailability and Pharmacokinetics of Calcium Dobesilate (Doxium®) in the Nasal Mucosal Tissue, Saliva and Blood of Treated Patients

Unknown status·UUniversity Hospital, Geneva··NCT04922996·14 enrolled

Chronic1 trial

Calcium Dobesilate for Chronic Venous Wounds

Suspended·FFundacion Iberoamericana Itaca·Phase 3·NCT00979836·230 enrolled

Rosacea1 trial

Combination Therapy for the Treatment of Rosacea

Completed·EEllen Marmur·Phase 1·NCT00945373·6 enrolled

Type 2 Diabetes Mellitus1 trial

Lung Function in Patients With Early Type 2 Diabetes Mellitus

Completed·LLiaoning University of Traditional Chinese Medicine·Phase 2/3·NCT03167918·200 enrolled

Tranexamic Acid1 trial

Effect of Tranexamic Acid and Calcium Dobesilate for Bleeding of Endometrial Origin

Completed·—·Phase 2/3·NCT06707051·100 enrolled

Diabetic Retinopathy1 trial

Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy

Unknown status·TTabriz University·Phase 4·NCT01382498·90 enrolled

Heavy Menstrual Bleeding1 trial

Efficacy of Calcium Dobesilate Versus Tranexamic Acid for Treating Heavy Menstrual Bleeding

Not yet recruiting·UUniversity of Health Sciences Lahore·N/A·NCT06763094·100 enrolled

T2DM1 trial

Effect of HMP on Diabetic Microangiopaemia in T2DM

Completed·—·Phase 4·NCT05095922·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Calcium Dobesilate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calcium Dobesilate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calcium Dobesilate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guizhou Bailing Group Pharmaceutical Co Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGuizhou Bailing Group Pharmaceutical Co Ltd

Calcium Dobesilate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ovarian Hyperstimulation Syndrome2 trials

Non-Proliferative Diabetic Retinopathy2 trials

COVID-191 trial

Blood Loss1 trial

Varicose veins1 trial

Efficacy and Safety1 trial

Tics1 trial

Chronic1 trial

Rosacea1 trial

Type 2 Diabetes Mellitus1 trial

Tranexamic Acid1 trial

Diabetic Retinopathy1 trial

Heavy Menstrual Bleeding1 trial

T2DM1 trial

References

Drug Info

Quick Facts

Related News